Background In contrast to type 2 diabetes, the association of body mass index (BMI) with glycemic control in type 1 diabetes (T1D) remains unclear. We investigated the relationship between BMI and average HbA 1c levels in subjects with T1D.
Introduction
Compared to subjects with type 2 diabetes (T2D) or the general population, it is well established that subjects with type 1 diabetes (T1D) tend to be leaner [1, 2] . However, recent epidemiologic studies have revealed that overweight conditions or obesity are increasing not only in T2D but also in T1D [1, [3] [4] [5] . In T1D, weight gain is usually observed during intensive insulin therapy [6] . There are several suggested mechanisms for insulin-induced weight gain. Because insulin is one of the main anabolic hormones, it promotes lipogenesis [7] and inhibits protein catabolism as well as lipolysis [7, 8] . In addition, insulin therapy results in the conservation of ingested calories by decreasing glycosuria [9] , alteration in appetite [10] , and allowing dietary flexibility in subjects with T1D [11] . In T1D, weight gain during insulin therapy might be considered as a normalization of lost weight and associated with improved glycemic control [1, 12] . However, recent studies demonstrated that excessive weight gain or becoming obese in subjects with T1D could lead to unfavourable outcomes such as elevated cholesterol levels and blood pressure [13, 14] , or microvascular complications [15] .
Because obesity is one of the most important risk factors for T2D, the association between body mass index (BMI) and glycemic control has been well established in T2D [2, 16] . However, few studies on the effects of weight on glucose control have been conducted in the T1D population. Previous studies demonstrated that higher BMI was associated with increased HbA 1c levels in T1D [4, 17] . In contrast, other studies with young adults showed an inverse relationship between BMI and glycemic control in T1D [13, 18] . One study showed no relationship between BMI and glycemic control based on subgroup or analytic method [13] . In addition to conflicting results in the association of BMI with glycemic control in T1D, the majority of studies were exclusively performed in adolescent or young adults. Therefore, we aimed to investigate the association between BMI and glycemic control in adult Korean subjects with T1D.
Materials and methods

Subjects and data collection
In this observational study, we recruited T1D subjects from five tertiary university-affiliated hospitals who were enrolled in the diabetic test strip reimbursement programme launched by the Korean National Health Insurance System in 2011 [19] . Based on clinical data from electronic medical records, we included subjects aged 18 years or older that met the following criteria of fasting C-peptide levels <0.8 ng/mL or stimulated C-peptide levels <1.8 ng/mL, or both positive for GAD and/or initial presentation with or a history of diabetes ketoacidosis (DKA) [19] [20] [21] . Among a total of 770 adults who met the inclusion criteria, we excluded those whose data were not available for BMI or HbA 1c levels (n = 18) and subjects who had a history of exocrine pancreas disease (chronic pancreatitis, undergone pancreatectomy, pancreatic neoplasia, etc.) (n = 33). We also excluded subjects with new-onset T2D initially presenting with DKA on a caseby-case basis. Finally, 719 subjects with T1D were observed between July 2011 and February 2014. During the follow-up, 89 and additional 50 adults were lost at 12 and 18 months, respectively. Finally, 19.3% of total participants were lost during the follow-up. The each ethics committee of five hospitals approved this study.
Clinical and laboratory measurements
For demographic data, the duration of diabetes, baseline BMI, waist circumference, and blood pressure were examined. Insulin regimen and the self-monitoring of blood glucose (SMBG) frequency were recorded. Duration of diabetes was defined as the time of year from the date of first T1D diagnosis to the date of study registration. BMI was calculated as body weight in kilogrammes divided by the square of height in metres. Overnight fast blood samples were obtained to measure HbA 1c , lipids, and basal C-peptide levels with standard laboratory methods. HbA 1c levels were obtained over 18 months from the enrollment time. The average HbA 1c levels from three measurements in 6-month intervals were used for analysis. Metabolic syndrome (MS) was diagnosed according to the revised NCEP-ATP III criteria [22] .
Statistical analysis
All continuous variables are presented as the mean ± standard deviation. Categorical variables are described as N (%). Differences were analysed using Student's t-test for continuous variables and the chi-square test for categorical variables. Relationship between baseline BMI and 18-month-average HbA 1c was assessed using a spline curve and Pearson's correlation analysis. Multiple linear regression analysis was used to investigate this association while controlling for other covariates. Statistical analyses were performed using PASW Statistics version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered significant.
Results
Study population characteristics
From this multi-centre observational cohort, a total of 719 subjects (men, 49%) with T1D were analysed in the present study. Baseline characteristics of the study participants are presented in Table 1 . Mean age and the duration of diabetes were 41.5 ± 13.9 and 11.3 ± 8.7 years, respectively. Mean baseline BMI of study subjects was 22.3 ± 2.9 kg/m 2 and 18% and 13% of patients were obese and had MS, respectively. Mean baseline HbA 1c levels were 8.3 ± 1.9% and 46% of patients reported to perform SMBG 1 or 2 times per day. The majority of subjects (66%) used insulin analogues with multiple daily injections (combination of long-acting and ultra-short-acting insulin analogues). The mean dose of insulin per body weight was 0.66 ± 0.27 U/kg.
Relationship between BMI and 18-month-average HbA 1c levels
The average HbA 1c level over 18 months was 8.2 ± 1.6%. Overall, baseline BMI and 18-month-average HbA 1c level showed a U-shaped correlation by spline curve analysis ( Figure 1A ). Based on these findings, we further analysed this association after stratifying BMI into three groups (group I, BMI <21 kg/m To investigate the relationship between BMI and glycemic control among the different BMI groups, each group was further divided into lower and higher BMI group by BMI tertile. As shown in Figure 2A , 18-month-average HbA 1c levels were lower in subjects with the higher BMI tertile in group I (Figure 2A ). The proportion of individuals with well-controlled glycemia (HbA 1c <7%) also increased in subjects with the higher BMI tertile in group I ( Figure 2D ). In group III, the 18-month-average HbA 1c levels were higher, and the proportion of individuals with well-controlled glycemia decreased in subjects with the higher BMI tertile ( Figure 2C and F) . As shown in correlation analysis, there was no significant difference in 18-month-average HbA 1c levels or the proportion of individuals with well-controlled glycemia between the lower and higher BMI tertile in group II ( Figure 2B and E).
Multivariate regression analysis
Differential associations between BMI and 18-monthaverage HbA 1c levels according to the different BMI ranges remained significant in multiple regression analysis (Table 2) . After adjustment for other covariates including age, sex, and MS, BMI showed a negative relationship with 18-month-average HbA 1c levels in group I. This relationship between BMI and 18-month-average HbA 1c levels in group I was not significant after additional adjustment for duration of diabetes or insulin regimen. According to the duration of diabetes, the subjects in group I showed different characteristics (Figure 3 ). The subjects with a longer duration of diabetes (≥10 years) had a higher BMI and a lower average HbA 1c level. In addition, the proportion of subjects with insulin doses less than 0.4 U/kg was lower in these subjects compared to the subjects with duration of diabetes <10 years. In contrast to group I, a positive relationship between BMI and 18-month-average HbA 1c levels was noted in group III and it remained significant in the fully adjusted model ( Table 2 ). The subjects in groups II and III did not show any differences in BMI, average HbA 1c levels, and insulin dose according to the duration of diabetes (data not shown).
We further investigated the relationship between 18-month-average HbA 1c levels and its associated factors by BMI strata (Table 3) . BMI had a negative tendency and positive association with 18-month-average HbA 1c levels in group I and III, respectively (standardized β = À0.10, p = 0.111 in group I and standardized β = 0.19, p = 0.005 in group III). Duration of diabetes showed a consistently negative association with average HbA 1c levels regardless of BMI strata. MS, which indirectly reflects insulin resistance in T1D, had a positive association with 18-month-average HbA 1c levels except for group I.
Discussion
In this observational study, a differential association between BMI and glycemic control in subjects with T1D according to BMI strata was observed. No association between BMI and average HbA 1c levels over 18 months in the subjects with a BMI of 21-23 kg/m 2 was found. However, subjects with a lower BMI (<21 kg/m 2 ) had an inverse association between BMI and 18-month-average HbA 1c levels, but a positive association between BMI and 18-month-average HbA 1c levels was observed in subjects with higher BMI (≥23 kg/m 2 ). Regarding baseline demographic findings, subjects with lower BMI showed a shorter duration of diabetes and inadequately a lower dose of insulin injection and subjects with higher BMI had more components of MS, which reflects insulin resistance.
There might be some possible reasons for these differential associations between BMI and glycemic control. Insulin therapy can increase weight by decreasing glycosuria [9] and affecting appetite [10] and metabolism [7, 8] . During the first year of therapy, insulin usually leads to weight gain of 1 or 2 kg in the subjects with T2D, and it may be more profound in subjects with T1D [12, 23] . As subjects with T1D are undergoing a catabolic state driven by insulin deficiency, lower weight may indicate inadequate insulin treatment. In this context, it is likely that the subjects with a lower BMI received an inadequate low dose of insulin resulting in less weight gain and poor glycemic control. Further, as subjects with lower BMI have lower fat-free mass as well as lower fat mass, the effectiveness of glucose utilization may be lower in these subjects. A previous study showed that weight gain by insulin therapy occurred not only in body fat but also in fat-free mass [24] . Therefore, we hypothesized that when subjects with lower BMI receive inadequately low doses of insulin, their glycemic control would get worse as a consequence of low utilization of glucose and further BMI lowering. Based on this hypothesis, we demonstrated that subjects with the lowest BMI had the worst glycemic control (Figure 2 ). In subjects with lower BMI levels (<21 kg/m 2 ), the association between BMI and glycemic control was not significant after further adjustment for the duration of diabetes. In our study, subjects with lower BMI had a relatively short duration of diabetes (10.4 years in subjects with BMI <21 kg/m 2 versus 12.3 years in subjects with BMI ≥23 kg/m 2 , p = 0.03). This might affect the inadequately low dose of insulin injection and glycemic control. Another possible mechanism might be associated with increased insulin sensitivity in lean subjects with T1D. As insulin sensitivity is usually inversely related to BMI, subjects with lower BMI are considered to have more correctable factors than those with higher BMI. Therefore, changes in blood glucose level may be greater in these subjects even with little modification of insulin dose, making blood glucose levels worse and more difficult to control in these subjects. Currently, there is no available insulin delivery device with half-unit dose accuracy in Korea, which might be one of the reasons for the inverse relationship between BMI and glycemic control in lean subjects with T1D.
Among subjects with higher BMI (≥23 kg/m 2 ), BMI showed a positive association with 18-month-average HbA 1c levels, which indicates poor glycemic control in the higher BMI group. It is well known that insulin therapy in T1D leads to weight gain as well as glycemic control. The DCCT trials and subsequent studies have shown that intensive insulin therapy increases the risk of overweight status compared to conventional insulin therapy [6, 13, 24] . In the present study, those with higher BMI (≥23 kg/m 2 ) received higher doses of insulin (34.8 U for subjects with BMI <21 kg/m 2 versus 46.5 U for subjects with BMI ≥23 kg/m 2 , p < 0.001). Although we did not observe secular changes in weight, subjects with higher BMI might have more weight gain during the treatment period compared to those with lower BMI. Several longitudinal studies have showed that subjects with more weight gain had a higher BMI during follow-up [13, 14] . Excessive weight gain with intensive insulin therapy is associated with unfavorable changes in lipid levels and blood pressure [13] . Furthermore, it aggravates central obesity, insulin resistance, and even atherosclerosis as similar to that seen in the insulin resistance syndrome in T2D [14] . Taken together, overweight or obesity status may have an adverse influence on glycemic control and other cardiovascular risk factors even in the higher BMI subjects with T1D. There are conflicting results in the literature regarding the association between BMI and glycemic control in subjects with T1D [4, 13, 17, 18] . Some studies showed a positive association between BMI and glycemic control [4, 17] while others did not [13, 18] . A longitudinal study observed a greater improvement in glycemic control in the T1D participants with lower BMI at baseline [4] . A similar result was reported in a large T1D cohort of more than 4000 subjects [17] . In contrast, other studies showed an inverse or no association between glycemic control and weight gain [13, 18] . Varied findings across studies may be attributed to diversity in study population, design, and analytic methods. As weight gain and glycemic control have a close relationship during treatment of T1D, it may be better to investigate the association between BMI and glycemic control based on longitudinal study design with consideration of further information such as insulin dose or regimen.
To analyse the study population, most studies of T1D have been performed in Caucasians. Compared to Caucasians, the incidence and positive rate for T1D autoantibodies are much lower in Asian populations. Furthermore, atypical types such as fulminant and slowly progressing T1D are more frequently reported in Asian countries, especially in adult T1D [5, 25] . In the present study, we observed the association of BMI with glycemic control in 719 subjects with T1D. To our knowledge, this is the first study to identify the association between BMI and glycemic control in the Asian population with a large sample size of adult T1D patients. However, there are several limitations in this study. First, the generalizability of our study may be limited because we recruited patients from only major five centres in metropolitan area. Second, the study population was originally recruited to evaluate the impact of the reimbursement insurance programme for T1D, only baseline BMI data were available in this study. Therefore, we could not establish the causal relationship between BMI and glycemic control. Third, we could not examine body composition, such as fat and fat-free mass, which can affect BMI changes and glycemic control. Last, we did not adjust for other potential confounders affecting glycemic control except for fasting c-peptide levels.
In conclusion, Korean subjects with T1D had a differential association between BMI and glycemic control according to the tested BMI ranges with a negative association in subjects with a lower BMI and a positive association in subjects with a higher BMI. These findings might suggest that the association between BMI and glycemic control is complicated and different BMI levels may involve this association in T1D. Further longitudinal study including body composition analysis will be needed to identify temporal and causal relationships between BMI and glycemic control in T1D.
